Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by StockNews.com to “Strong-Buy”

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Tuesday.

A number of other brokerages have also weighed in on COLL. Jefferies Financial Group restated a “hold” rating and issued a $37.00 price objective (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Needham & Company LLC restated a “buy” rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Truist Financial boosted their price objective on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, February 26th. Finally, Piper Sandler restated an “overweight” rating and issued a $39.00 price objective (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Price Performance

COLL stock opened at $35.48 on Tuesday. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10. Collegium Pharmaceutical has a one year low of $20.83 and a one year high of $40.95. The stock has a market cap of $1.16 billion, a PE ratio of 30.07 and a beta of 1.03. The firm has a 50 day simple moving average of $37.02 and a two-hundred day simple moving average of $31.14.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The business had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. On average, analysts predict that Collegium Pharmaceutical will post 5.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Nations Financial Group Inc. IA ADV purchased a new position in Collegium Pharmaceutical during the 1st quarter valued at $386,000. HighPoint Advisor Group LLC purchased a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth about $514,000. Penn Capital Management Company LLC purchased a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth about $9,755,000. Avidity Partners Management LP grew its position in shares of Collegium Pharmaceutical by 3.2% in the 4th quarter. Avidity Partners Management LP now owns 361,363 shares of the specialty pharmaceutical company’s stock worth $11,123,000 after buying an additional 11,163 shares during the period. Finally, Third Avenue Management LLC purchased a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth about $2,558,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.